Remember Me
Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hedgecoe, Adam (2010)
Publisher: SAGE
Languages: English
Types: Article
Subjects: BJ, H1
Over the past few years, considerable interest has been paid to the way in which social expectations (hopes, hypes, fears) about new genomic technologies help shape, and in themselves are shaped by, emerging technologies, regulatory regimes and social concerns. In comparison, little attention has been paid to the role of expectations in related, but non-scientific discourses, such as bioethics. Drawing on a review of publications addressing the ethical issues associated with pharmacogenetics, this paper presents a detailed critique of bioethicists’ contribution to these debates. The review highlights how, almost a decade after bioethical debate around pharmacogenetics started, and in contrast to the profession’s self-perception as a form of regulator, bioethicists still largely restrict themselves to reviews of possible ethical issues raised by this technology, rather than critiquing others’ positions and arguing for specific points of view. In addition the paper argues that bioethicists tend to: accept unquestioningly scientists’ expectations about the development and ethical issues raised by pharmacogenetics; ignore contributions from bioethicists who do question these expectations; and engage in an ethical debate, the boundaries of which have been laid down and defined by academic and industry scientists. The paper concludes by offering some possible explanations for why the bioethical discourse has taken this form.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Akhtar, Saghir (2002) 'Pharmacogenomics: are Pharmacists Ready for Genotyped Prescribing?', The Pharmaceutical Journal 268 (2 March): 296-299.
    • Anderson D.C., Gomez-Mancilla B., Spear B.B., Barnes D.M., Cheeseman K., Shaw P.M., Friedman J., McCarthy A., Brazell C. , Ray S.C., McHale D., Hashimoto L., Sandbrink R., Watson M.L., Salerno R.A., Cohen N. and Lister C.E. on behalf of The Pharmacogenetics Working Group. (2002) 'Elements Of Informed Consent For Pharmacogenetic Research; Perspective Of The Pharmacogenetics Working Group', The Pharmacogenomics Journal 2(5): 284-292.
    • Anderson, W., C. Fitzgerald and P.K. Manasco (1999) 'Current and Future Applications of Pharmacogenomics', New Horizons: Science and Practice of Acute Medicine 7(2) (April): 262-269
    • Bell, John (1997) 'Genetics Of Common Disease', Philosophical Transactions of the Royal Society of London 352: 1051-1055
    • Benatar D. (2006) 'Bioethics And Health And Human Rights: A Critical View', Journal of Medical Ethics 32: 17-20.
    • Bosk, Charles L. (1999) 'Professional Ethicist Available: Logical, Secular, Friendly', Daedelus 128: 47-68
    • Brown, Nik, Brian Rappert, and Andrew Webster (eds) (2000) Contested Futures: A Sociology of Prospective Science and Technology (Aldershot: Ashgate).
    • Burke, Wylie and Bruce M. Psaty (2007) 'Personalized Medicine In The Era Of Genomics', Journal of the American Medical Association 298(14): 1682- 1684
    • Clayton, Ruth (1986) 'Review of “What sort of people should there be?” ', Journal of Medical Ethics 12(3): 163-164.
    • Coats, Andrew (2000) 'Pharmacogenomics: Hope or Hype?', International Journal of Cardiology 76: 1-3
    • De Vries, Raymond (2003) 'How Can We Help? From “Sociology In” To “Sociology Of” Bioethics', Journal of Law, Medicine and Ethics 32(2): 279-292
    • DeVries, Raymond & Conrad, Peter (1998) 'Why Bioethics Needs Sociology', in Raymond DeVries & Janardan Subedi (eds.) Bioethics and Society: Constructing the Ethical Enterprise Upper Saddle River, NJ: Prentice Hall): 233-257
    • Eichelbaum, Michel, Magnus Ingelman-Sundberg and William E. Evans (2006) 'Pharmacogenetics And Individualised Drug Therapy', Annual Review of Medicine 57: 119-137.
    • Elliott, Carl (2002) 'Diary', London Review of Books 24(23), (2 November): 36-37.
    • Elliott, Carl (2004) 'Six Problems With Pharma-Funded Bioethics', Stud. Hist. Phil. Biol. & Biomed. Sci. 35: 125-129
    • Elliott, Carl (2005) 'Adventure! Comedy! Tragedy! Robots! How Bioethicists Learned To Stop Worrying And Embrace Their Inner Cyborgs', Journal of Bioethical Inquiry 18-23
    • Evans W. E. and Relling M. (1999) 'Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics', Science 286: 487-491;
    • Evans, John H. (2000) 'A Sociological Account of the Growth of Principalism', Hastings Center Report 30: 31-38;
    • Evans, John H. (2002) Playing God?: Human Genetic Engineering and the Rationalisation of Public Bioethical Debate. (Chicago. University of Chicago Press)
    • Evans, J.H. (2006) 'Between Technocracy And Democratic Legitimation: A Proposed Compromise Position For Common Morality Public Bioethics', Journal of Medicine and Philosophy 31: 213-234
    • Faunce, TA (2005) 'Will International Human Rights Subsume Medical Ethics? Intersections In The UNESCO Universal Bioethics Declaration', Journal of medical Ethics 31: 173-178
    • Fox, Daniel (1993) 'View the Second', Hastings Center Report Vol 23 (NovemberDecember): S13.
    • Ginsburg G. and McCarthy J. (2001) 'Personalized Medicine: Revolutionizing Drug Discovery And Patient Care', Trends in Biotechnology. 19(12): 491-499.
    • Fox, Renée and Judith Swazey (2008) Observing Biethics (Oxford & New York: Oxford University Press)
    • Guyer, Ruth L. and Jonathon D. Moreno (2004) 'Slouching Towards Policy: Lazy Bioethics And The Perils Of Science Fiction', American Journal of Bioethics 4(4): W14-17
    • Hedgecoe Adam (2001) 'Schizophrenia And the Narrative of Enlightened Geneticization', Social Studies of Science 31(6): 875-911.
    • Hedgecoe Adam M. and Paul Martin (2003) 'The Drugs Don't Work: Expectations And The Shaping Of Pharmacogenetics', Social Studies of Science, 33(3): 327-364
    • Hedgecoe, Adam M. (2003) 'Terminology And The Construction Of Scientific Disciplines: The Case Of Pharmacogenomics', Science, Technology and Human Values 28(4): 513-537.
    • Hedgecoe, Adam M. (2004) 'Critical Bioethics: Beyond the Social Science Critique of Applied Ethics', Bioethics 18(2): 120-143.
    • Hoffmaster, Barry (1992) 'Can Ethnography Save the Life of Medical Ethics?', Social Science and Medicine 35: 1421-1431
    • Johnson J. (2003) 'Pharmacogenetics: Potential For Individualized Drug Therapy Through Genetics', Trends in Genetics 19(11): 660- 666.
    • Jonsen, Albert (1998) The Birth of Bioethics (New York and Oxford: Oxford University Press).
    • Kahn, Jonathon (2006) 'Race, Pharmacogenetics And Marketing: Putting Bidil In Context', American Journal of Bioethics 6(5):W1-W5
    • Kleinman, Arthur (1999) 'Moral Experience and Ethical Reflection: Can Ethnography Reconcile Them? A Quandary for “The New Bioethics” ', Daedelus 128: 69-97.
    • Lau, Kit Fun and Hakan Sakul (2000) 'Chapter 23: Pharmacogenomics', in J. Allen (ed.) Annual Reports in Medicinal Chemistry (Elsevier): 261-269.
    • Lazarou, J., Pomeranz B.H. and Corey P.N. (1998) 'Incidence of Adverse Drug Reactions in Hospitalized Patients', Journal of the American Medical Association 279(15):1200-1205.
    • Lewins, Frank (1998) 'The Development Of Bioethics And The Issue Of Euthanasia: Regulating, De-Regulating Or Re-Regulating?', Journal of Sociology 34(2): 123- 134
    • Lichter J and J. Kurth (1997) 'The Impact Of Pharmacogenetics On The Future Of Healthcare', Current Opinion in Biotechnology 8: 692-695
    • Lindpaintner, Klaus (1999) 'Genetics In Drug Discovery And Development: Challenge And Promise Of Individualizing Treatment In Common Complex Disease', British Medical Bulletin 55(2): 471-491
    • Lindpaintner, Klaus (2003a) 'Pharmacogenetics And The Future Of Medical Practice', J. Mol Med 81: 141-153
    • Lindpaintner, Klaus (2003b) 'Pharmacogenetics: A New - Or Not So New? - Concept In Healthcare' The Geneva Papers on Risk and Insurance 28(2): 316-330
    • Lindpaintner, K, E. Foot, M. Caulfield, and I. Hall (2001) 'Pharmacogenetics: Focus On Pharmacodynamics', International Journal of Pharmaceutical Medicine 15: 74- 82
    • MacKenzie, Donald (1990) Inventing accuracy: a historical sociology of nuclear missile guidance (Cambridge, Mass.: MIT Press)
    • Maitland van der zee A.H., de Boer A. and Leufkens H.G.M. (2000) 'The Interface Between Pharmacoepidemiology And Pharmacogenetics', European Journal of Pharmacology 410: 121-130
    • Mancinelli L. Cronin M. and Sadée W. (2000) 'Pharmacogenomics: The Promise Of Personalized Medicine' AAPS Pharmsci 2(1) (7 March) Article 4
    • Martin, Paul (1999) 'Genes as Drugs: The Social Shaping of Gene Therapy and the Reconstruction of Genetic Disease', Sociology of Health and Illness 21: 517-38.
    • Martin Paul, Graham Lewis, Andrew Smart, and Andrew Webster (2006) False Positive? The commercial and clinical development of pharmacogenetics (SATSU, University of York and IGBiS, University of Nottingham)
    • Messikomer C.M, Renee Fox & Judith P. Swazey (2001) 'The Presence and Influence of Religion in American Bioethics', Perspective in Biology and Medicine 44: 485- 508
    • Millstone, Eric (2000) 'Analysing biotechnology's traumas', New Genetics & Society 19(2): 119-132.
    • Moyses C. (1999) 'Pharmacogenetics, Genomics, Proteomics: The New Frontiers In Drug Development', International Journal of Pharmaceutical Medicine 13: 197- 202
    • Myers, Greg (1990) 'Making a Discovery: Narratives of Split Genes', in Christopher Nash (ed.), Narrative in Culture: The Uses of Storytelling in the Sciences, Philosophy, and Literature (London: Routledge): 102-25.
    • Myers, Greg (1991) 'Stories and Styles in Two Molecular Biology Review Articles', in Charles Bazerman and James Paradis (eds), Textual Dynamics of the Professions (Madison: University of Wisconsin Press): 45-75
    • Persing B.F. and Cheek D.J. (2000) 'Pharmacogenomics', Nursing Clinics of North America 35(4): 975-980.
    • Phillips K., Veenstra D., Oren E., Lee L. and Sadée W. (2001) 'Potential Role Of Pharmacogenomics In Reducing Adverse Drug Reactions: A Systematic Review', Journal of the American Medical Association 286(18): 2270-2279.
    • Piquette-Miller M. and Grant DM (2007) 'The Art And Science Of Personalized Medicine', Clinical Pharmacology and Therapeutics 81(3): 311-315
    • PriceWaterHouse Coopers (2001) Pharma 2005: An Industrial Revolution in R&D http://www.pwcglobal.com/gx/eng/about/ind/pharma/industrial_revolution.pdf
    • Potter, Van Rensselaer (1971) Bioethics: Bridge to the Future (Englewood Cliffs, N.J.: Prentice-Hall)
    • Reich Warren T. (1995) ‚Introduction' in Reich (ed.) The Encyclopedia of Bioethics revised ed. (New York: Simon Shuster Macmillan).
    • Robert, Jason Scott (2000) 'Schizophrenia Epigenesis', Theoretical Medicine and Bioethics 21: 191-215
    • Vaszar, L.T. Rosen GD, and Raffin TA (2002) 'Pharmacogenomics And The Challenge To Privacy', The Pharmacogenomics Journal 2002; 2: 144-147.
    • Williamson, Laura (2008) 'The Quality Of Bioethics Debate: Implications For Clinical Ethics Committees', Journal of medical ethics 34: 357-360.
    • Wolpe P.R. (2000) 'From the Bedside to Boardroom: Sociological Shifts and Bioethics', HEC Forum 2000; 12: 191-201
    • Neil D. and Craigie J. [2004] 'The Ethics of Pharmacogenomics', Monash Bioethics Review 23(2): 9-20 [Ethicists]
    • Lunshof J. & de Wert G. [2004] 'Pharmacogenomics, Drug Development, And Ethics: Some Points To Consider', Drug Development Research 62:112-116 [Ethicists]
    • Sutrop, M [2004] 'Pharmacogenetics: Ethical issues' Bioethics 18(4): iii-viii [Ethicist]
    • van Delden, J, Bolt, I, Kalis, A, Derijks, J, Leufkens, H [2004] 'Tailor-Made Pharmacotherapy: Future Developments And Ethical Challenges In The Field Of Pharmacogenomics', Bioethics 18(4]: 303-321 [Ethicists; Scientists]
    • Smart A. Martin, P. Parker, M. [2004] 'Tailored Medicine: Whom Will it Fit? The Ethics of Patient and Disease Stratification', Bioethics 18(4): 322-343 [Social Scientists; Ethicist]
    • Netzer, C. Biller-Andorno, N.[2004] 'Pharmacogenetic Testing, Informed Consent and the Problem of Secondary Information', Bioethics 18(4): 344-359 [Scientists; Ethicists]
    • Schubert, L. [2004] 'Ethical Implications of Pharmacogenetics - Do Slippery Slope Arguments Matter?', Bioethics 18(4): 361-378 [Ethicist]
    • Mordini, E [2004] 'Ethical Considerations On Pharmacogenomics', Pharmacological Research 49(4): 375-379 [Ethicist]
    • Morley, K, Hall, W [2004] 'Using Pharmacogenetics And Pharmacogenomics In The Treatment Of Psychiatric Disorders: Some Ethical And Economic Considerations', Journal Of Molecular Medicine 82(1): 21-30. [Scientist; Ethicist]
    • Weijer C. Miller PB [2003] 'Protecting Communities In Pharmacogenetic And Pharmacogenomics Research', The Pharmacogenomics Journal: 1-8 [Ethicist]
    • Lee S-J.S. [2003] 'Race, Distributive Justice And The Promise Of Pharmacogenomics', American Journal of Pharmacogenomics 3(6):385-392 [Ethicist]
    • Williams-Jones B, Corrigan O [2003] 'Rhetoric And Hype: Where's The “Ethics” In Pharmacogenomics?', American Journal of Pharmacogenomics. 3(6):375-83 [Ethicist; Social Scientist]
    • Freund C, Clayton E [2003] 'Pharmacogenomics And Children: Meeting The Ethical Challenges'. American Journal of Pharmacogenomics 3(6):399-404 [Scientist; Ethicist]
    • Vaszar L, Cho M, Raffin T [2003] 'Privacy Issues In Personalized Medicine', Pharmacogenomics (2):107-12 [Scientist; Ethicist; Scientist]
    • Lipton, P [2003] 'Pharmacogenetics: The Ethical Issues', Pharmacogenomics Journal 3(1): 14-16 [Ethicist]
    • Wertz, D [2003] 'Ethical, Social And Legal Issues In Pharmacogenomics', Pharmacogenomics Journal 3(4): 194-196 [Social Scientist]
    • Paul, N, Roses, A [2003] 'Pharmacogenetics And Pharmacogenomics: Recent Developments, Their Clinical Relevance And Some Ethical, Social, And Legal Implications', Journal Of Molecular Medicine 81(3): 135-140 [Ethicist; Scientist (Industry)]
    • Møldrup C. [2002] 'When Pharmacogenomics Goes Public', New Genetics and Society 21(1): 29-37 [Scientist]
    • Rothstein, M, Epps, P [2001] 'Ethical And Legal Implications Of Pharmacogenomics', Nature Reviews Genetics 2: 228-231 [Ethicists]
    • Issa A [2001] 'Clinical And Moral Challenges Of Pharmacogenomics', The National Catholic Bioethics Quarterly 1(4):541-53 [Ethicist]
    • Moldrup C. [2001] 'Ethical, Social And Legal Implications Of Pharmacogenomics: A Critical Review', Community Genetics 4(4): 204-14 [Scientist]
    • March R, Cheeseman K, Doherty M. [2001] 'Pharmacogenetics--Legal, Ethical And Regulatory Considerations', Pharmacogenomics 2(4): 317-27 [Scientists (Industry)]
    • Renegar G, Rieser P, Manasco P. [2001] 'Family Consent And The Pursuit Of Better Medicines Through Genetic Research', Journal of Continuing Education of Health Professions 21(4): 265-70 [Scientists (Industry)]
    • Robertson J [2001] 'Consent And Privacy In Pharmacogenetic Testing', Nature Genetics 28(3):207-9 [Ethicist]
    • Thomas S. [2001] 'Pharmacogenetics: The Ethical Context', The pharmacogenomics journal 1: 239-242 [Ethicist]
    • Clarke A, English V, Harris H, Wells F [2001] 'Ethical considerations', International Journal of Pharmaceutical Medicine 15:89-94 [Scientist; Ethicist; Scientist; Scientist (industry)]
    • Issa, A, Keyserlingk, E [2000] 'Apolipoprotein E Genotyping For Pharmacogenetic Purposes In Alzheimer's Disease: Emerging Ethical Issues', Canadian Journal Of Psychiatry 45(10): 917-922 [Ethicist]
    • Issa, A [2000] 'Ethical Considerations In Clinical Pharmacogenomics Research', Trends In Pharmacological Sciences 21(7): 247-249 [Ethicist]
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

  • WT

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok